- Novel targeted therapeutics: inhibitors of MDM2, ALK and PARPYuan Yuan
Division of Medical Oncology and Hematology, Loma Linda University Medical Center, Loma Linda, CA 92354, USA
J Hematol Oncol 4:16. 2011..Olaparib, another oral small-molecule PARP inhibitor, demonstrated encouraging single-agent activity in patients with advanced breast or ovarian cancer. There are 5 other PARP inhibitors currently under active clinical investigation...